Shane Cooke Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Cooke PRTA stock SEC Form 4 insiders trading

Shane has made over 1 trades of the Prothena plc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 3,182,253 units of PRTA stock worth $79,429,035 on 3 February 2014.

The largest trade he's ever made was selling 3,182,253 units of Prothena plc stock on 3 February 2014 worth over $79,429,035. On average, Shane trades about 3,182,253 units every 0 days since 2014.

You can see the complete history of Mr. S stock trades at the bottom of the page.

Shane Cooke biography

Shane M. Cooke serves as Independent Director of the Company., since December 2012. He is the former President of Alkermes plc (a biopharmaceutical company), a position he held from 2011 to 2018. Prior to that, he served as Head of Elan Drug Technologies and Executive Vice President of Elan Corporation, plc (from 2007 to 2011), where he also served as Chief Financial Officer (from 2001 to 2011) and as a director (from 2005 to 2011). Mr. Cooke has also held a number of senior positions in finance in the banking and aviation industries. He is also a director of Alkermes plc, Endo International plc and UDG Healthcare plc. Mr. Cooke earned his Bachelor of Commerce and Master of Accounting degrees from University College Dublin, Ireland, and is a chartered accountant. He has served on our Board since 2012.

What is the salary of Shane Cooke?

As the Independent Director of Prothena plc, the total compensation of Shane Cooke at Prothena plc is $193,444. There are 15 executives at Prothena plc getting paid more, with Wagner Zago having the highest compensation of $3,341,640.

How old is Shane Cooke?

Shane Cooke is 57, he's been the Independent Director of Prothena plc since 2012. There are 8 older and 16 younger executives at Prothena plc. The oldest executive at Prothena Corporation plc is Christopher Henney, 78, who is the Independent Director.

Insiders trading at Prothena plc

Over the last 12 years, insiders at Prothena plc have traded over $79,429,035 worth of Prothena plc stock and bought 2,987,732 units worth $75,619,043 . The most active insiders traders include Capital, Llc Eco R1, Co Plc Elan Corp Plc Elan S... und Helen Susan Kim. On average, Prothena plc executives and independent directors trade stock every 21 days with the average trade being worth of $946,769. The most recent stock trade was executed by Karin L Walker on 24 January 2024, trading 5,000 units of PRTA stock currently worth $67,650.

What does Prothena plc do?

prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f

Complete history of Mr. S stock trades at Prothena plc

Prothena plc executives and stock owners

Prothena plc executives and other stock owners filed with the SEC include:

• Wagner Zago,
  Chief Scientific Officer
• Gene Kinney,
  President, Chief Executive Officer, Director
• Michael Malecek,
  Chief Legal Officer and Company Secretary
• Tran Nguyen,
  Chief Financial Officer, Chief Operating Officer
• Carol Karp,
  Chief Regulatory Officer
• Radhika Tripuraneni,
  Chief Development Officer
• Dr. Gene G. Kinney Ph.D.,
  Pres, CEO & Director
• Dr. Hideki Garren M.D., Ph.D.,
  Chief Medical Officer
• Tran B. Nguyen M.B.A.,
  CFO & Chief Strategy Officer
• Carol D. Karp,
  Chief Regulatory Officer
• Michael J. Malecek,
  Chief Legal Officer & Company Sec.
• Brandon S. Smith,
  Chief Operating Officer
• Paula Cobb,
  Independent Director
• Lars Ekman,
  Independent Chairman of the Board
• Dennis Selkoe,
  Independent Director
• Shane Cooke,
  Independent Director
• Richard Collier,
  Independent Director
• Christopher Henney,
  Independent Director
• K. Anders Harfstrand,
  Independent Director
• Brandon Smith,
  Chief Business Officer
• Oleg Nodelman,
  Independent Director
• Karin Walker,
  Chief Accounting Officer, Controller
• Dr. Radhika Tripuraneni M.D., M.P.H.,
  Chief Devel. Officer
• Dr. Hideki Garren,
  Chief Medical Officer
• Dr. Radhika Tripuraneni M.P.H., M.D.,
  Chief Devel. Officer
• Jennifer Zibuda,
  Director of Investor Relations & Communication
• Dr. Wagner M. Zago,
  Chief Scientific Officer
• Karin L. Walker CPA, CPA,
  Chief Accounting Officer & Controller
• Sarah B. Noonberg,
  Chief Medical Officer
• Arthur W Homan,
  Chief Legal Officer
• Tara Nickerson,
  Chief Business Officer
• Martin Koller,
  Chief Medical Officer
• Capital, Llc Eco R1,
  10% owner
• Sanjiv Patel,
  
• Co Plc Elan Corp Plc Elan S...,
  
• Dale B. Schenk,
  President and CEO
• John Randall Fawcett,
  Controller
• David B. Mc Ninch,
  Chief Commercial Officer
• William H. Jr. Dunn,
  
• Helen Susan Kim,
  
• Daniel G Welch,
  
• Hideki Garren,
  Chief Medical Officer
• David A Ford,
  Chief People Officer